Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Povidone iodine/dexamethasone ophthalmic suspension - CLS Pharmaceuticals/Takeda

Next Previous
Search
Drug Profile

Povidone iodine/dexamethasone ophthalmic suspension - CLS Pharmaceuticals/Takeda

Alternative Names: FST-100; PVP-I/dexamethasone; SHP-640; TAK 640

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CLS Pharmaceuticals
  • Developer Takeda
  • Class Anti-inflammatories; Antiemetics; Antiseptics; Disinfectants; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Oxidants; Pregnadienetriols; Pyrrolidinones; Skin disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Infectious conjunctivitis

Most Recent Events

  • 23 Feb 2021 Discontinued - Phase-II for Infectious conjunctivitis in India, Brazil (Ophthalmic) before February 2021 (Takeda's pipeline, February 2021)
  • 23 Feb 2021 Discontinued - Phase-III for Infectious conjunctivitis in USA, Australia, Austria, Canada, Colombia, Estonia, Hungary, Israel, Poland, Puerto Rico, South Africa, Spain (Ophthalmic) before February 2021 (Takeda's pipeline, February 2021)
  • 16 May 2019 Shire completes a phase III trial for Infectious conjunctivitis (adenoviral conjunctivitis) in Puerto Rico and USA (NCT02998554)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top